Psoriasis News and Research

Latest Psoriasis News and Research

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

The National Institutes of Health has awarded Benaroya Research Institute at Virginia Mason a 7-year grant to lead the Immune Tolerance Network.

24 Jan 2014

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

To advance understanding of psoriasis—the most common autoimmune disease in the country, affecting up to 7.5 million Americans—and help scientists and clinicians improve treatments and patient outcomes, the National Psoriasis Foundation and the Consortium of Rheumatology Researchers of North America, Inc. will create the first psoriasis registry co-developed and co-administered by a nonprofit.

10 Jan 2014

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells-macrophages-are stimulated in response to pathogens.

27 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability.

20 Dec 2013

Sanofi US launches second PiPH innovation challenge to improve drug development process

Today, Sanofi US launched its second Partners in Patient Health Innovation Challenge: Collaborate | Innovate, which will award $100,000 to the winning team. This year's theme is "Co-Creating for Breakthroughs: Moving toward a collaborative research and development ecosystem."

10 Dec 2013

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.

9 Dec 2013

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

PhotoMedex, Inc. announced today the termination of the exclusive distribution agreement between its wholly-owned subsidiary Radiancy, Inc. and Ya-Man Ltd. for the Japanese market due to, among other things, disputed marketing expenses of approximately $1 million and the failure of Ya-Man to meet its minimum purchase obligations under the agreement.

6 Dec 2013

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

6 Dec 2013

Teenage bereavement linked to asthma hospitalization risk

Research shows that children who experience bereavement during late adolescence are at increased risk for asthma hospitalizations.

19 Nov 2013

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

A novel combination anti-psoriasis therapy has potential for superior and longer-lasting therapeutic effects than current topical treatments by targeting genetic abnormalities in deeper layers of the skin. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14.

15 Nov 2013

Coding variants in immune disease-related genes play only small part in risk for psoriasis

Coding variants in immune disease-related genes play only a small part in the overall genetic risk for psoriasis, according to a new study led by Anhui Medical University and BGI.

10 Nov 2013

Four-year study to develop targeted approach to psoriasis treatment

A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.

8 Nov 2013

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

PhotoMedex, Inc. today reported financial results for the three and nine months ended September 30, 2013.

6 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

IFPA brings attention to the need for improving treatment, care for psoriasis

Today, on World Psoriasis Day, the International Federation of Psoriasis Associations, IFPA, brings attention to the need for improving the availability of treatment and care for psoriasis - a disease that affects more than 125 million people all over the world.

29 Oct 2013

Psoriasis News and Research

Latest Psoriasis News and Research

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Sanofi US launches second PiPH innovation challenge to improve drug development process

Janssen announces first-of-its-kind pediatric HIV treatment donation program

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Teenage bereavement linked to asthma hospitalization risk

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

Coding variants in immune disease-related genes play only small part in risk for psoriasis

Four-year study to develop targeted approach to psoriasis treatment

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

IFPA brings attention to the need for improving treatment, care for psoriasis

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Psoriasis News and Research

Latest Psoriasis News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in